Skip to content

Erasca, Inc. ERAS Cash & Equivalents

Cash & Equivalents at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$9.57B-12.0%
Eli Lilly logo
Eli LillyLLY
$5.28B+70.8%
Pfizer logo
PfizerPFE
$1.76B+18.8%
Amgen logo
AmgenAMGN
$559M+10.0%
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
$440.94M+32.2%
Tango Therapeutics logo
Tango TherapeuticsTNGX
$159.97M+162%

Other financials

Income statement

See full
Operating income-$187.9M-427%
Net income-$183.4M-492%
EPS (diluted)-$0.60-445%

Balance sheet

See full
Total debt$46.0M-9.6%
Total equity$393.5M-1.5%
Total assets$461.2M-2.1%

Cash flow

See full
Operating cash flow-$27.4M+13.2%
CapEx$36.0K-56.6%
Free cash flow-$27.4M+13.3%

Valuation

See full
Market cap$4.25B+1,196%
Enterprise value$4.25B+1,265%

Returns & leverage

See full
Return on equity-69.9%+77.1pp
Debt / equity0.1×0.0×
Current ratio9.5×-2.8×

Where this comes from

Reported directly by Erasca, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The official record: Erasca, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Erasca, Inc.'s cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Erasca, Inc.'s cash & equivalents?
Erasca, Inc. (ERAS) reported cash & equivalents of $47.26M in Q1 2026.
How has Erasca, Inc.'s cash & equivalents changed year-over-year?
Erasca, Inc.'s cash & equivalents decreased by 33.0% year-over-year, from $70.48M to $47.26M.
What is the long-term trend for Erasca, Inc.'s cash & equivalents?
Over 5 years (2020 to 2025), Erasca, Inc.'s cash & equivalents has grown at a 2.5% compound annual growth rate (CAGR), from $65.38M to $73.81M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.